Lumbiganon Pisake, Thinkhamrop Jadsada, Thinkhamrop Bandit, Tolosa Jorge E
Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, 123 Mitraparb Road, Amphur Muang, Khon Kaen, Thailand, 40002.
Cochrane Database Syst Rev. 2014 Sep 14;2014(9):CD004070. doi: 10.1002/14651858.CD004070.pub3.
The incidence of chorioamnionitis occurs in between eight and 12 women for every 1000 live births and 96% of cases of chorioamnionitis are due to ascending infection. Following spontaneous vaginal delivery, 1% to 4% of women develop postpartum endometritis. The incidence of neonatal sepsis is 0.5% to 1% of all infants born. Maternal vaginal bacteria are the main agents for these infections. It is reasonable to speculate that prevention of maternal and neonatal infections might be possible by washing the vagina and cervix with an antibacterial agent for all women during labour. Chlorhexidine belongs to the class of compounds known as the bis-biguanides. Chlorhexidine has antibacterial action against a wide range of aerobic and anaerobic bacteria, including those implicated in peripartal infections.
To evaluate the effectiveness and side effects of chlorhexidine vaginal douching during labour in reducing maternal and neonatal infections (excluding group B streptococcal and HIV).
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 June 2014), reference lists of retrieved reports and journal letters and editorials.
Randomized or quasi-randomized trials comparing chlorhexidine vaginal douching during labour with placebo or other vaginal disinfectant to prevent (reduce) maternal and neonatal infections (excluding group B streptococcal and HIV).
Two review authors independently assessed trial eligibility and quality, extracted and interpreted the data. A third review author analyzed and interpreted the data. The fourth author also interpreted the data.
We included three studies (3012 participants). There was no evidence of an effect of vaginal chlorhexidine during labour in preventing maternal and neonatal infections. Although the data suggest a trend in reducing postpartum endometritis, the difference was not statistically significant (three trials, 3012 women, risk ratio 0.83; 95% confidence interval 0.61 to 1.13).Assessment of the quality of the evidence using GRADE indicated that the levels of evidence for all primary outcomes and one important secondary outcome were low to moderate.
AUTHORS' CONCLUSIONS: There is no evidence to support the use of vaginal chlorhexidine during labour in preventing maternal and neonatal infections. There is a need for a well-designed randomized controlled trial using appropriate concentration and volume of vaginal chlorhexidine irrigation solution and with adequate sample size.
绒毛膜羊膜炎的发病率为每1000例活产中有8至12名妇女发病,96%的绒毛膜羊膜炎病例是由上行感染引起的。自然阴道分娩后,1%至4%的妇女会发生产后子宫内膜炎。新生儿败血症的发病率为所有出生婴儿的0.5%至1%。产妇阴道细菌是这些感染的主要病原体。合理推测,在分娩期间对所有妇女用抗菌剂冲洗阴道和宫颈可能预防母婴感染。洗必泰属于双胍类化合物。洗必泰对多种需氧菌和厌氧菌具有抗菌作用,包括那些与围产期感染有关的细菌。
评估分娩期间洗必泰阴道灌洗在减少母婴感染(不包括B族链球菌和艾滋病毒)方面的有效性和副作用。
我们检索了Cochrane妊娠与分娩组试验注册库(2014年6月30日)、检索报告的参考文献列表以及期刊信件和社论。
比较分娩期间洗必泰阴道灌洗与安慰剂或其他阴道消毒剂以预防(减少)母婴感染(不包括B族链球菌和艾滋病毒)的随机或半随机试验。
两位综述作者独立评估试验的合格性和质量,提取并解释数据。第三位综述作者分析并解释数据。第四位作者也对数据进行了解释。
我们纳入了三项研究(3012名参与者)。没有证据表明分娩期间阴道使用洗必泰在预防母婴感染方面有效果。尽管数据显示在减少产后子宫内膜炎方面有一定趋势,但差异无统计学意义(三项试验,3012名妇女,风险比0.83;95%置信区间0.61至1.13)。使用GRADE评估证据质量表明,所有主要结局和一项重要次要结局的证据水平为低到中等。
没有证据支持分娩期间使用阴道洗必泰来预防母婴感染。需要进行一项设计良好的随机对照试验,使用合适浓度和体积的阴道洗必泰冲洗液,并具有足够的样本量。